Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.
NEWS
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.
A recap of where life sciences cash has been flowing the past week.
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.
Biopharma companies raking in the cash with investment rounds and IPO announcements.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS